5-Desfluoro Sitagliptin

For research use only. Not for therapeutic Use.

  • CAT Number: R015065
  • CAS Number: 1345822-86-7
  • Molecular Formula: C₁₆H₁₉F₅N₅O₅P
  • Molecular Weight: 487.32
  • Purity: ≥95%
Inquiry Now

<p>
<span style="color:#000000;"><span style="font-size:12px;"><span style="font-family:arial,helvetica,sans-serif;">5-Desfluoro Sitagliptin (CAS&nbsp;1345822-86-7)&nbsp;is a metabolite of Sitagliptin phosphate. Sitagliptin is a trizolopyrazine dipeptidyl peptidase IV inhibitor. Sitagliptin has recently been approved for the therapy of type II diabetes.</span></span></span></p>


Catalog Number R015065
CAS Number 1345822-86-7
Synonyms

(R)-3-Amino-4-(2,4-difluorophenyl)-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)butan-1-one-phosphate

Molecular Formula C₁₆H₁₉F₅N₅O₅P
Purity ≥95%
Storage -20°C
IUPAC Name (3R)-3-amino-4-(2,4-difluorophenyl)-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]butan-1-one;phosphoric acid
InChI InChI=1S/C16H16F5N5O.H3O4P/c17-10-2-1-9(12(18)6-10)5-11(22)7-14(27)25-3-4-26-13(8-25)23-24-15(26)16(19,20)21;1-5(2,3)4/h1-2,6,11H,3-5,7-8,22H2;(H3,1,2,3,4)/t11-;/m1./s1
InChIKey ZUZNSXPDPFKCSY-RFVHGSKJSA-N
SMILES C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)CC(CC3=C(C=C(C=C3)F)F)N.OP(=O)(O)O
Reference

<p>
<span style="color:#000000;"><span style="font-size:12px;"><span style="font-family:arial,helvetica,sans-serif;">1.Kim, Dooseop, et al. &quot;(2 R)-4-Oxo-4-[3-(trifluoromethyl)-5, 6-dihydro [1, 2, 4] triazolo [4, 3-a] pyrazin-7 (8 H)-yl]-1-(2, 4, 5-trifluorophenyl) butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.&quot;&nbsp;<i style="font-family: Arial, sans-serif; font-size: 13px;">Journal of medicinal chemistry</i>&nbsp;48.1 (2005): 141-151.<br />
2.Ahr&eacute;n, Bo, et al. &quot;Beta-cell expression of a dominant-negative HNF-1&alpha; compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in mice.&quot;&nbsp;<i style="font-family: Arial, sans-serif; font-size: 13px;">European journal of pharmacology</i>&nbsp;521.1-3 (2005): 164-168.<br />
3.Bergman, Arthur J., et al. &quot;Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.&quot;&nbsp;<i style="font-family: Arial, sans-serif; font-size: 13px;">Clinical therapeutics</i>&nbsp;28.1 (2006): 55-72.</span></span></span></p>

Request a Quote